9 results
The aim of this study is to determine whether multiparametric MRI (mpMRI) of the bladder, in combination with an outpatient biopsy for histological confirmation, is a faster, safer, cheaper and therefore more cost-effective way to detect or…
To prospectively validate the safety and efficiency of management according to the YEARS algorithm to safely rule out clinically suspected PE in patients with active malignancy to be compared with `standard' management by CTPA alone in a…
The overall aim of this strategy study is to directly compare the effectiveness of treatment with levetiracetam or valproic acid in glioma patients with de novo seizures. In addition, we aim to examine the level of toxicity, the impact of seizures…
To identify molecular biomarker profiles that are associated with cervical tumorigenesis, and that can be used for development of an algorithm for detection of low grade CIN1, CIN2, CIN3 and cervical cancer. The algorithm should provide advice for…
To investigate the effects of ICIs (anti-CTLA4, anti-PD1, combination anti-CTLA4/PD1) on vascular inflammation (PET-CT) in stage III melanoma patients. We hypothesize that the increase in vascular inflammation will be greater in the exposure group…
The overarching objective of this master protocol is to study the risk factors (personal, clinical and lifestyle factors) for-, and consequences of- , changes of nutritional status (both over- and undernutrition) in children with cancer. Based on…
To evaluate and compare the survival outcome of patients with first recurrence of glioblastoma undergoing surgical debulking/resection followed by either implantation of the SC9 device and repeat BBB opening in association with carboplatin…
The aim of this study is to evaluate the safety and efficacy of the esophageal partially covered SEMS. We will pay specific attention to recurrent dysphagia rates, migration rates and pain.
Determine the safety (oncological outcome and toxicity) of an comprehensive treatment combining recent advances in the treatment of high risk prostate cancer